Skip to content

Mild Hypothermia for COVID-19 ARDS

Application of Mild Hypothermia for COVID-19 Acute Respiratory Distress

Status
Withdrawn
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04570462
Enrollment
0
Registered
2020-09-30
Start date
2020-05-18
Completion date
2020-12-31
Last updated
2021-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID19 ARDS

Brief summary

Some patients with COVID have abnormally high carbon dioxide and low oxygen levels despite being on the ventilator. The hypothesis of the study is that the application of mild hypothermia to patients with COVID will decrease their metabolic rate and improve their oxygenation and carbon dioxide levels.

Detailed description

A significant contributor to the morbidity and mortality from COVID-19 is from the abnormal carbon dioxide and oxygen levels in COVID-19 patients. Metabolic studies done on COVID-19 patients have shown that these patients have abnormally high metabolic rates. High metabolic rates results in increased carbon dioxide production and increased oxygen usage, both of which can result in high carbon dioxide and low oxygen levels. As some patients with severe COVID-19 continue to have high carbon dioxide levels and/or low oxygen levels despite being on the ventilator, it is hypothesized that decreasing the metabolic rate in these COVID-19 patients will help their oxygen and carbon dioxide levels. Mild hypothermia is currently used in comatose survivors of cardiac arrest to improve mortality and neurological outcomes. Mild hypothermia is also an effective way to reduce metabolic demand. The aim is to apply mild hypothermia to COVID-19 patients to decrease metabolic rate in order to improve their oxygen and carbon dioxide levels. Although the application for mild hypothermia has been widely adopted in some patient populations, it has never been applied in COVID-19 patients. If we can develop a strategy to help improve the oxygen and carbon dioxide levels in COVID-19 patients, it may lead to improvements in their overall outcomes.

Interventions

OTHERHypothermia Via Cooling Machine- Arctic Sun 5000

Initiate hypothermia using the Arctic Sun.The Arctic Sun 5000® is set to a temperature of 34.5 C to lower the body temperature. Duration of hypothermia will be 48 hours after which the subject will be rewarmed. Metabolic rate, or indirect Calorimetry, will be assessed at baseline, day 1 of hypothermia, day 2 of hypothermia before rewarming, and after full rewarming. CBC, basic metabolic profile, magnesium, phosphorus, coagulation profile, ABG, inflammatory markers would be drawn every 12 hours during hypothermia until subject has achieved full rewarming and once after full rewarming. The entire hypothermia procedure will last 48 hours. Acceptable rewarming range is a temperature of 36.5C to 37.5C. The subject body temperature rewarming is typically set over 6-8 hours. Therefore, the final 6-8 hours of the 48 hour time period is set to rewarm the subject.

Sponsors

Northwell Health
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 100 Years
Healthy volunteers
No

Inclusion criteria

1. Provision of signed and dated informed consent form from Legally Authorized Representative. 2. Stated willingness to comply with all study procedures and availability for the duration of the study 3. Male or female, aged 18 years or above 4. COVID positive 5. On mechanical ventilation with either: refractory respiratory acidosis (ph ≤ 7.20), hypercarbia (pCO2 ≥ 55 mmHg), refractory hypoxia (pO2/FIO2 \<150), or plateau pressures \>30

Exclusion criteria

1. Bleeding (active bleeding, platelets less than 50,000) 2. Uncontrolled cardiac arrhythmia 3. History of cryoglobulinemia, major trauma, pregnancy 4. Active non-COVID-19 infection that is not controlled with antibiotic or antifungal regimen

Design outcomes

Primary

MeasureTime frameDescription
Changes in metabolic requirement during and after hypothermiaEvery 12 hours through study completion an average of 4 daysindirect calorimeter measurements (Kcal/day)

Secondary

MeasureTime frameDescription
Changes in oxygen requirements and levels during and after hypothermiaEvery 12 hours through study completion, an average of 4 daysABG, PaO2 (mmHg)
length of intubationthrough study completion, an average of 4 daysnumber of hours intubated
Changes in carbon dioxide levels during and after hypothermiaEvery 12 hours through study completion an average of 4 daysmeasured by ABG, PaCO2 mmHg
does application of hypothermia reduce pro inflammatory responsethrough study completion an average of 4 daysESR (mm/hr)

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026